Covid-19: Aurobindo Pharma working on ‘multiple’ vaccines

G Naga Sridhar Hyderabad | Updated on February 12, 2021

Drug-maker to double production capacity to 480 million doses by 2021

Aurobindo Pharma is presently working on ‘multiple’ vaccines for Covid-19 pandemic.

It is also in the process of doubling its production capacity from current 220 million doses in multi-dose presentation to a capacity of 480 million doses by June 2021.

Referring to Covid-19 vaccines, the company told investors: “Multiple vaccines are under development leveraging the inherent execution capabilities and collaborative strengths.”

The Hyderabad-based company’s in-house Covid vaccine: SARS COV-2 vaccine candidate is based on the company’s proprietary, replication, competent, attenuated recombinant vesicular stomatitis vaccine delivery platform.

Covaxx trials

Aurobindo also entered into an exclusive license agreement with Covaxx, a US based company to develop, commercialise and manufacture UB-612, first Multitope Peptide-based Vaccine for Covid-19 in India and to the United Nations Children's Fund (UNICEF).

It showed “promising results for safety and immunogenicity in Covaxx’s phase-I clinical trial conducted in Taiwan,” the company said.

In addition, Aurobindo also collaborated with the Council of Scientific and Industrial Research (CSIR) to develop multiple vaccines for Covid-19.

Other vaccines

Aurobindo is also developing pneumococcal conjugate vaccine (PCV) which has an addressable global market size of $6.2 billion.

The drug-maker successfully completed the Phase-I and Phase-II studies. “Phase-III clinical study is expected to be initiated in March 2021,” it said. It expects to file the product with regulatory authorities in Q4 of FY22.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 12, 2021
This article is closed for comments.
Please Email the Editor